The Background and Future of Quizartinib for AML

Video

Mark J. Levis, MD, PhD, Johns Hopkins University, discusses the background and future of quizartinib for FLT3-ITD acute myeloid leukemia at the 2013 Chemotherapy Foundation Symposium, which took place from November 6-8.

Clinical Pearls

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the background and future of quizartinib for FLT3-ITD acute myeloid leukemia at the 2013 Chemotherapy Foundation Symposium, which took place from November 6-8.

  • Quizartinib could play a crucial role in the treatment of FLT3-ITD acute myeloid leukemia
  • Quizartinib has produced many clinically meaningful responses
  • The phase IIb study will analyze 30 mg and 60 mg doses
Recent Videos
Related Content
FDA Grants NX-5948 Fast Track Designation in R/R Waldenström Macroglobulinemia

FDA Grants NX-5948 Fast Track Designation in R/R Waldenström Macroglobulinemia

Jordyn Sava
December 19th 2024
Article

The FDA granted fast track designation to NX-5948 for treating relapsed/refractory Waldenström macroglobulinemia after 2 or more lines of therapy, including a BTK inhibitor.

Read More

Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

Rohit Gosain, MD;Rahul Gosain, MD
April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen

Standard Belzutifan Dose Equally Effective as Higher Dose in ccRCC

Standard Belzutifan Dose Equally Effective as Higher Dose in ccRCC

Jordyn Sava
December 18th 2024
Article

In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating belzutifan for advanced clear cell renal cell carcinoma treatment.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

Nichole Tucker;Cyrus M. Khan, MD
May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

Promising Advances in Hematology: Key Findings From ASH 2024

Promising Advances in Hematology: Key Findings From ASH 2024

Jordyn Sava
December 17th 2024
Article

Here are some of the highlights from this year's 2024 ASH Annual Meeting & Exposition.

Read More

Multidisciplinary GVHD Care Reveals Unmet Needs and Opportunities

Multidisciplinary GVHD Care Reveals Unmet Needs and Opportunities

Jonah Feldman
December 16th 2024
Article

Memorial Sloan Kettering Cancer Center physicians describe challenges in diagnosis, patient care, and the potential expansion of telehealth in this continuation of November's coverfeature.

Read More